Oncolytics Biotech Stock Net Asset
| ONCY Stock | USD 0.94 0.01 1.05% |
Oncolytics Biotech fundamentals help investors to digest information that contributes to Oncolytics Biotech's financial success or failures. It also enables traders to predict the movement of Oncolytics Stock. The fundamental analysis module provides a way to measure Oncolytics Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncolytics Biotech stock.
Oncolytics | Net Asset |
Oncolytics Biotech Company Net Asset Analysis
Oncolytics Biotech's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Oncolytics Biotech Net Asset | 38.82 M |
Most of Oncolytics Biotech's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncolytics Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Oncolytics Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Oncolytics Biotech is extremely important. It helps to project a fair market value of Oncolytics Stock properly, considering its historical fundamentals such as Net Asset. Since Oncolytics Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oncolytics Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oncolytics Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Oncolytics Total Assets
Total Assets |
|
Based on the recorded statements, Oncolytics Biotech has a Net Asset of 38.82 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Oncolytics Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncolytics Biotech's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncolytics Biotech could also be used in its relative valuation, which is a method of valuing Oncolytics Biotech by comparing valuation metrics of similar companies.Oncolytics Biotech is currently under evaluation in net asset category among its peers.
Oncolytics Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Oncolytics Biotech from analyzing Oncolytics Biotech's financial statements. These drivers represent accounts that assess Oncolytics Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Oncolytics Biotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 136.7M | 122.5M | 94.0M | 128.1M | 118.2M | 137.3M | |
| Enterprise Value | 123.1M | 91.6M | 53.4M | 116.8M | 83.7M | 118.0M |
Oncolytics Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Oncolytics Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Oncolytics Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Oncolytics Biotech's value.| Shares | Bmo Capital Markets Corp. | 2024-06-30 | 37.4 K | Virtu Financial Llc | 2024-06-30 | 27.4 K | Brave Asset Management Inc | 2024-09-30 | 25 K | Newman Dignan & Sheerar Inc | 2024-09-30 | 22 K | Financial Advisory Corp /ut/ /adv | 2024-09-30 | 20.6 K | Lpl Financial Corp | 2024-09-30 | 20.5 K | Head & Associates, Llc | 2024-09-30 | 17.4 K | C2p Capital Advisory Group Llc Dba Prosperity Capital Advisors | 2024-09-30 | 15 K | Ausdal Financial Partners Inc | 2024-09-30 | 14 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 277 K | Seeds Investor Llc | 2024-09-30 | 189.9 K |
Oncolytics Fundamentals
| Return On Equity | -1.38 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 60.06 M | ||||
| Shares Outstanding | 77.07 M | ||||
| Shares Owned By Insiders | 3.81 % | ||||
| Shares Owned By Institutions | 1.76 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Earning | (2.06) X | ||||
| Price To Book | 11.35 X | ||||
| EBITDA | (33.71 M) | ||||
| Net Income | (27.75 M) | ||||
| Cash And Equivalents | 32.36 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 423 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.42 X | ||||
| Book Value Per Share | 0.37 X | ||||
| Cash Flow From Operations | (28.45 M) | ||||
| Short Ratio | 3.51 X | ||||
| Earnings Per Share | (0.26) X | ||||
| Target Price | 6.97 | ||||
| Beta | 1.51 | ||||
| Market Capitalization | 73.54 M | ||||
| Total Asset | 38.82 M | ||||
| Retained Earnings | (446 M) | ||||
| Working Capital | 33.94 M | ||||
| Current Asset | 14.39 M | ||||
| Current Liabilities | 2.91 M | ||||
| Net Asset | 38.82 M |
About Oncolytics Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncolytics Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncolytics Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncolytics Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.